If the FDA approves GLP-1 weight loss patches in the future, patients using the patches may experience similar side effects as subcutaneous GLP-1 injections, including GI-related adverse effects
The direct-to-consumer health-care startup Ro launched a new free tool Tuesday to help patients determine whether their insurance covers a buzzy class of weight loss and diabetes drugs called GLP-1s
individuals with cardiovascular or renal disease)
However, despite the anti-diabetic and anti-obesity functions, of these dual and triple agonists, the long-term safety, cardiovascular, and renal benefits of these multi-target therapies need further validation
Its also worth noting that these medications carry some known side effects, such as gastrointestinal discomfort and potential strain on the kidneys, but reproductive harm has not been documented
This has raised concerns about the potential risks associated with using these drugs outside their approved indications
